Amneal Pharmaceuticals Announces Closing of Acquisition of Kashiv

What Happened
Amneal Pharmaceuticals, Inc. (AMRX) filed an 8‑K on August 10, 2026 reporting that it has closed an acquisition (the “Acquisition”) of Kashiv. The filing covers entry into a material definitive agreement, completion of the asset acquisition, creation of a direct financial obligation tied to the transaction, and the issuance of unregistered equity securities as part of the deal. Amneal also issued a press release announcing the closing (attached as Exhibit 99.1).

Key Details

• Filing date: August 10, 2026 (Form 8‑K).
• Items reported: 1.01 (Material Definitive Agreement), 2.01 (Completion of Acquisition), 2.03 (Creation of a Direct Financial Obligation), 3.02 (Unregistered Sales of Equity Securities), 7.01 (Regulation FD Disclosure), 9.01 (Financial Statements and Exhibits).
• Press release: Amneal issued a press release on the Closing Date announcing the Acquisition (Exhibit 99.1 to the 8‑K).
• Financial statements: Amneal intends to file the financial statements of Kashiv required by applicable rules (to be furnished later in an amendment or subsequent filing).

Why It Matters
For investors, this 8‑K confirms Amneal completed a strategic acquisition that affects the company’s assets, balance sheet and equity structure. The filing indicates new contractual obligations (debt or other financing) were created and that Amneal issued unregistered shares as part of the transaction—both items can affect leverage and shareholder dilution. The company will provide the acquired business’s financials in a follow‑up filing, which investors should review to assess the acquisition’s financial impact.